Abstract | BACKGROUND: METHODS: Twenty-nine subjects with bipolar depression received a double-blind, randomized, subanesthetic dose (.5 mg/kg) ketamine infusion. Of the patients for whom Shank3 levels were collected, 15 completed baseline 3-Tesla MRI and 17 completed post- ketamine [(18)F]-FDG PET. RESULTS: Higher baseline Shank3 levels predicted antidepressant response at Days 1 (r=-.39, p=.047), 2 (r=-.45, p=.02), and 3 (r=-.42, p=.03) and were associated with larger average (r=.58, p=.02) and right amygdala volume (r=.65, p=.009). Greater baseline Shank3 also predicted increased glucose metabolism in the hippocampus (r=.51, p=.04) and amygdala (r=.58, p=.02). LIMITATIONS: Limitations include the small sample size, inability to assess the source of peripheral Shank3, and the lack of a placebo group for baseline Shank3 levels and comparative structural/functional neuroimaging. CONCLUSIONS:
|
Authors | Robin Ortiz, Mark J Niciu, Nada Lukkahati, Leorey N Saligan, Allison C Nugent, David A Luckenbaugh, Rodrigo Machado-Vieira, Carlos A Zarate Jr |
Journal | Journal of affective disorders
(J Affect Disord)
Vol. 172
Pg. 307-11
(Feb 01 2015)
ISSN: 1573-2517 [Electronic] Netherlands |
PMID | 25451430
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Copyright | Published by Elsevier B.V. |
Chemical References |
- Antidepressive Agents
- Biomarkers
- Receptors, N-Methyl-D-Aspartate
- N-Methylaspartate
- Ketamine
|
Topics |
- Adult
- Aged
- Amygdala
(metabolism)
- Antidepressive Agents
(therapeutic use)
- Biomarkers
(blood)
- Bipolar Disorder
(blood, drug therapy)
- Double-Blind Method
- Female
- Humans
- Ketamine
(therapeutic use)
- Male
- N-Methylaspartate
(therapeutic use)
- Receptors, N-Methyl-D-Aspartate
(blood)
- Treatment Outcome
|